Evidence map›Paper›PMID 10490830›Full record

ArticleOncogene1999

p300 functions as a transcriptional coactivator for the TAL1/SCL oncoprotein.

S Huang, Y Qiu, R W Stein, S J Brandt

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 81 citations in OpenAlex.

  1. Noncoding RNA,Molecular and cellular biology · 2025
    Article
  2. Article
  3. Transcription Factor TAL1 in Erythropoiesis.Advances in experimental medicine and biology · 2024
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

S HuangDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, TN 37232, USA.
Y Qiu
R W Stein
S J Brandt
Vanderbilt University Medical Center · US

Funding

REGULATION AND FUNCTION OF THE TAL1/SCL GENER01HL049118 · NHLBI · VANDERBILT UNIVERSITY · PI BRANDT, STEPHEN J. · 1998 to 2011
$2.4M
FACTORS IMPORTANT IN BETA2 TARGETED ACTIVATIONR01DK055091 · NIDDK · VANDERBILT UNIVERSITY · PI STEIN, ROLAND W · 1998 to 2001
$539k
NHLBI NIH HHS R01 HL49118NIDDK NIH HHS R01 DK55091
6 · The paper itself

Abstract

Activation of the TAL1 (or SCL) gene, originally identified through its involvement by a recurrent chromosomal translocation, is the most frequent gain-of-function mutation recognized in T-cell acute lymphoblastic leukemia (T-ALL). The TAL1 proteins contain a basic helix - loop - helix (bHLH) motif characteristic of a large family of transcription factors that control transcription from an E box target element as heterodimers with the E2A- and HEB-encoded gene products. Gene knockout studies in mice indicate that this transcription factor is required for embryonic and adult hematopoiesis, and considerable evidence suggests it has specific functions in terminal erythroid differentiation. We investigated whether the broadly expressed nuclear protein p300, known to function as a coactivator for other bHLH proteins involved in cellular differentiation, also interacts with TAL1. p300 was found to coimmunoprecipitate with Tal1 in extracts from murine erythroleukemia (MEL) cells induced to differentiate with dimethylsulfoxide (DMSO), and p300 and Tal1 were observed in a common E box DNA-binding complex in extracts from differentiating MEL cells. p300 also interacted with Tal1 in protein pulldown assays, suggesting this was a direct interaction. Finally, p300 augmented transcription by Tal1 from an E box-containing promoter and by a GAL4-Tal1 fusion from a promoter containing the GAL4 DNA-binding element. Deletion analysis identified the bHLH domain of Tal1 and amino-terminal sequences of p300 as necessary for p300-stimulated transactivation and Tal1-p300 interaction in vitro. These results indicate that recruitment of the transcriptional coactivator p300 can positively regulate TAL1-directed gene expression. The dependence of their interaction in MEL cells on addition of a differentiation inducer suggests, further, that this TAL1-p300 complex may have an important role in terminal erythroid differentiation.

Indexed as

Proto-Oncogene ProteinsTranscriptional ActivationTranscription Factors3T3 CellsAnimalsBasic Helix-Loop-Helix ProteinsCell DifferentiationDimerizationDimethyl SulfoxideDNADNA-Binding ProteinsE1A-Associated p300 ProteinHumansMiceNuclear ProteinsPrecipitin TestsBasic Helix-Loop-Helix ProteinsDimethyl SulfoxideDNADNA-Binding ProteinsE1A-Associated p300 ProteinEp300 protein, mouseNuclear ProteinsProto-Oncogene ProteinsRecombinant Fusion ProteinsTAL1 protein, humanTal1 protein, mouseT-Cell Acute Lymphocytic Leukemia Protein 1Trans-ActivatorsTranscription Factors

Identifiers

PMID10490830
OpenAlexW2331070544

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.